
House bill proposes stricter oversight on China biotech deals
A new proposal aims to include biotechnology in the COINS Act in response to recent acquisitions by Pfizer and Bristol Myers involving Chinese companies. The move reflects growing concerns about China’s advancements in drug manufacturing and their potential impact on national security, offering valuable insights for American industry and national competitiveness.










